Chronimed suspends Quick Check shipments:
This article was originally published in Clinica
Chronimed has suspended all shipments of its Quick Check reagent strip in the US because of unresolved issues with its supplier, Diagnostic Solutions, and the FDA. Chronimed has started negotiations to acquire the manufacturing rights of the strip test from Diagnostic Solutions. The company, based in Minneapolis, Minnesota, must also resolve questions the FDA has about inconsistent strip test results before shipments can resume.
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.